Vera Therapeutics Inc
NASDAQ:VERA
Vera Therapeutics Inc
NASDAQ:VERA
Price:
43.5 USD
2.79%
Market Closed
Updated:
May 3, 2024
Vera Therapeutics Inc
Cash from Financing Activities
|
Vera Therapeutics Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Vera Therapeutics Inc
NASDAQ:VERA
|
Cash from Financing Activities
$133.5m
|
CAGR 3-Years
16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Vera Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
133.5m
USD
133.5m
USD
Based on the financial report for Dec 31, 2023, Vera Therapeutics Inc's Cash from Financing Activities amounts to 133.5m USD.
What is Vera Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
16%
16%
Over the last year, the Cash from Financing Activities growth was 31%. The average annual Cash from Financing Activities growth rates for Vera Therapeutics Inc have been 16% over the past three years .
You don't have any saved screeners yet
